First dogs in the UK treated with new bee and wasp venom immunotherapy

The University of Glasgow’s Small Animal Hospital has begun treating dogs in the United Kingdom with a groundbreaking form of immunotherapy designed to combat severe allergic reactions to bee and wasp stings. This marks the first instance of such treatment being offered in the country, offering hope to pet owners whose dogs suffer from life-threatening anaphylactic responses to insect bites. The hospital is among a select group of global specialists capable of administering this disease-modifying therapy, which aims to train the immune system to tolerate future exposures to venom and thus reduce the risk of recurring severe reactions. The treatment, known as Hymenoptera Venom Immunotherapy (VIT), was originally developed for human patients but has now been adapted for use in dogs. It involves a carefully managed process of exposing the animal to escalating doses of bee or wasp venom over time, allowing the body to build tolerance and significantly lower the chances of a severe allergic response upon future encounters. The therapy is considered a major advancement in veterinary medicine, especially for dogs prone to anaphylaxis, a condition that can lead to collapse, breathing difficulties, and even death. According to the hospital, the treatment has already been administered to multiple dogs, with promising results. Clinical studies conducted by the institution indicate that many dogs receiving VIT demonstrate robust protection against repeated anaphylactic episodes. These findings come amid growing recognition of the dangers posed by insect venom allergies in canine populations. Insect venom allergy is regarded as one of the most severe acute allergic conditions affecting dogs, with reactions often occurring within minutes of a sting. In rare but critical cases, these reactions can escalate to life-threatening complications. Professor Ana Rostaher, a leading authority in veterinary immunology at the University of Glasgow, leads the initiative. She and her team have played a key role in advancing the understanding and application of VIT in dogs. Their work has shown that the treatment carries a favorable safety profile when administered under professional oversight, making it a viable long-term solution for dogs with chronic allergies. The process of administering VIT begins with a comprehensive diagnostic phase involving allergy testing to confirm the presence of venom sensitivity. Once diagnosed, the dog enters an induction phase, during which controlled amounts of venom are introduced to the body. This stage is closely monitored to ensure the treatment progresses safely. Long-term maintenance therapy typically spans several years, requiring regular follow-ups to assess the dog’s response and adjust dosages as needed. One of the first dogs to receive the treatment was Amber, a Vizsla owned by Claire and Matthew Preece from Stratford-upon-Avon. Amber suffered a severe allergic reaction to a bee sting in July 2021, when an unseen bee entered their home through an open window. Within moments, the dog exhibited alarming signs, including unusual barking, hives, and vomiting, before collapsing and requiring immediate medical attention. The incident left the family deeply anxious, particularly during warm weather and outdoor activities, fearing another similar episode. After learning about the availability of VIT, the Preeces decided to pursue the treatment at the University of Glasgow’s Small Animal Hospital. They describe the decision as both necessary and hopeful, believing the therapy could offer their dog a better quality of life and greater security against future threats. “We chose immunotherapy to reduce the fear and uncertainty associated with Amber’s condition,” they stated. The case highlights the real-world impact of this emerging treatment and its potential to transform care for dogs with severe insect venom allergies.